FIB-4 como predictor de ACLF en cirrosis hepática
No Thumbnail Available
Date
2024-08-12
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
La cirrosis hepática es una enfermedad grave que implica fibrosis hepática y la formación de nódulos, siendo la etapa final de la enfermedad hepática. Las principales causas incluyen hepatitis viral, alcoholismo, y enfermedades metabólicas. La descompensación aguda de la cirrosis, como la ACLF, tiene un alto índice de mortalidad y afecta múltiples órganos. En Perú, la prevalencia y mortalidad de ACLF son significativas, destacando la necesidad de herramientas predictivas como FIB-4 para mejorar el manejo clínico. No existen estudios previos en la región, lo que refuerza la relevancia del proyecto para futuras investigaciones locales. Objetivo: Demostrar si FIB-4 predice ACLF en cirrosis hepática en el servicio de gastroenterología del Hospital Regional Docente de Trujillo durante el periodo 2018-2022.
Material y métodos: estudio Observacional, analítico, retrospectivo de pruebas diagnósticas. La población estará conformada por los pacientes diagnosticados de cirrosis hepática hospitalizados en el servicio de gastroenterología en el Hospital Regional Docente de Trujillo durante el periodo 2018-2022. Se aplicará el índice FIB-4 al ingreso hospitalario con un punto de corte de 4,22, y se evaluará la presencia de ACLF durante seis meses usando la calculadora de puntaje OF CLIF-C. Se determinarán la sensibilidad, especificidad, valor predictivo positivo y negativo, y la razón de verosimilitud positiva y negativa. Finalmente, se calculará la curva ROC y el área bajo la curva (AUC) para el índice FIB-4.
Abstract Liver cirrhosis is a serious disease that involves liver fibrosis and nodule formation, being the final stage of liver disease. The main causes include viral hepatitis, alcoholism, and metabolic diseases. Acute decompensation of cirrhosis, such as ACLF, has a high mortality rate and affects multiple organs. In Peru, the prevalence and mortality of ACLF are significant, highlighting the need for predictive tools such as FIB-4 to improve clinical management. There are no previous studies in the region, which reinforces the relevance of the project for future local research. Objective: To demonstrate whether FIB-4 predicts ACLF in liver cirrhosis in the gastroenterology service of the Trujillo Regional Teaching Hospital during the period 2018-2022. Material and methods: Observational, analytical, retrospective study of diagnostic tests. The population will be comprised of patients diagnosed with liver cirrhosis hospitalized in the gastroenterology service at the Trujillo Regional Teaching Hospital during the period 2018-2022. The FIB-4 index will be applied upon hospital admission with a cut-off point of 4.22, and the presence of ACLF will be assessed for six months using the OF CLIF-C score calculator. Sensitivity, specificity, positive and negative predictive value, and positive and negative likelihood ratio will be determined. Finally, the ROC curve and the area under the curve (AUC) for the FIB-4 index will be calculated.
Abstract Liver cirrhosis is a serious disease that involves liver fibrosis and nodule formation, being the final stage of liver disease. The main causes include viral hepatitis, alcoholism, and metabolic diseases. Acute decompensation of cirrhosis, such as ACLF, has a high mortality rate and affects multiple organs. In Peru, the prevalence and mortality of ACLF are significant, highlighting the need for predictive tools such as FIB-4 to improve clinical management. There are no previous studies in the region, which reinforces the relevance of the project for future local research. Objective: To demonstrate whether FIB-4 predicts ACLF in liver cirrhosis in the gastroenterology service of the Trujillo Regional Teaching Hospital during the period 2018-2022. Material and methods: Observational, analytical, retrospective study of diagnostic tests. The population will be comprised of patients diagnosed with liver cirrhosis hospitalized in the gastroenterology service at the Trujillo Regional Teaching Hospital during the period 2018-2022. The FIB-4 index will be applied upon hospital admission with a cut-off point of 4.22, and the presence of ACLF will be assessed for six months using the OF CLIF-C score calculator. Sensitivity, specificity, positive and negative predictive value, and positive and negative likelihood ratio will be determined. Finally, the ROC curve and the area under the curve (AUC) for the FIB-4 index will be calculated.
Description
Keywords
FIB-4, ACLF, Cirrosis Hepática